Teladoc Health Inc SEC Filings

Jason Eric Evans, a director of Teladoc Health, Inc. (TDOC), reported transactions dated 09/19/2025 on Form 4. The filing shows acquisition of 1,016 restricted stock units that convert one-for-one into common shares, and the reporting person acquired 1,016 shares of common stock on the same date. After the transactions, the reporting person beneficially owned 8,129 shares of common stock and 4,066 derivative securities representing underlying common stock. The RSUs were part of a grant originally awarded on 09/20/2023 totaling 12,195 RSUs with a stated vesting schedule. The form is signed by an attorney-in-fact on 09/22/2025.

Teladoc Health insider transactions by Charles Divita III: On 09/10/2025, 39,160 restricted stock units vested and were treated as an acquisition (one-for-one conversion to common stock), increasing his reported beneficial ownership. On 09/11/2025 he sold 16,787 shares to cover tax withholding at an average price of $7.5913, leaving 179,014 shares beneficially owned according to the Form 4. The filing notes a grant on June 10, 2024 of 469,924 RSUs that vest over time, with one-third vesting on the first anniversary and the remainder in eight equal quarterly installments.

Teladoc Health (TDOC) filed a Form 144 reporting a proposed sale of 16,787 common shares held at Fidelity Brokerage Services with an aggregate market value of $127,435.15. The filing shows an approximate sale date of 09/11/2025 on the NYSE. The shares were acquired the prior day, 09/10/2025, through restricted stock vesting from the issuer and were granted as compensation. The filer reports no securities sold by the same person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Teladoc Health insider transactions by Fernando M. Rodrigues Reporting person Fernando M. Rodrigues, President of BetterHelp, reported restricted stock unit vesting and subsequent sales. On 08/29/2025, 5,491 and 1,041 restricted stock units were deemed acquired and converted one-for-one into shares. On 09/02/2025, 2,383 shares were sold at $7.585 per share to cover tax withholding related to the RSU vesting. On 09/03/2025, an additional 4,149 shares were sold at $7.59 per share under a Rule 10b5-1 plan adopted November 18, 2024 and amended November 27, 2024. Following these transactions the reporting person beneficially owned 27,457 shares and had 6,252 shares outstanding from recent grants.

Carlos Nueno, President, International at Teladoc Health, Inc. (TDOC), reported stock-unit conversions and a small sale to cover taxes. On 08/29/2025 Mr. Nueno had 1,056 performance stock units convert to common shares and two restricted stock unit vesting events converting 3,100 and 4,556 RSUs into common shares. Following those conversions his reported beneficial ownership rose stepwise to 26,357 shares. On 09/02/2025 he sold 3,998 shares at $7.585 per share to satisfy tax withholding, leaving 22,359 shares reported as beneficially owned. The filing also shows the counts of derivative awards remaining after the transactions: 1,056 performance-stock-unit underlying shares and restricted-stock-unit balances of 3,100 and 4,556 as reported in Table II. The transactions were reported on a Form 4 signed by an attorney-in-fact on 09/03/2025.

Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, reported equity award vesting and a sale to cover taxes. On 08/29/2025 he was granted 1,505 performance stock units and two restricted stock unit awards of 4,418 and 5,350 RSUs (each converts one-for-one into common stock). The filing shows vesting schedules: the performance units vest one-third on March 1, 2024, then in eight substantially equal quarterly installments; the RSUs follow a similar one-third/quarterly pattern with specified start dates.

On 09/02/2025 he sold 5,867 shares at $7.585 to satisfy tax withholding arising from the vesting, leaving beneficial ownership at 75,179 shares following the reported transactions.

Bliss Kelly, President, U.S. Group Health at Teladoc Health (TDOC), reported equity award activity and a small sale to cover taxes. On 08/29/2025 she received 1,189 performance stock units (convertible one-for-one to common shares) and two restricted stock unit grants of 3,488 and 4,858 units. A sale on 09/02/2025 disposed of 4,700 shares at $7.585 per share to satisfy tax withholding related to vesting. After the reported transactions, the filing shows Ms. Kelly beneficially owned 55,101 shares of common stock and held derivative/award balances underlying 2,375, 6,976, and 29,151 shares in the listed award categories.

Murthy Mala, Chief Financial Officer of Teladoc Health (TDOC), reported equity award vesting and a small sale to cover tax withholding. On 08/29/2025 the reporting person had performance stock units and multiple restricted stock unit awards convert to common stock, adding 22,788 shares on that date and increasing beneficial ownership to 155,231 shares prior to the sale. On 09/02/2025 the reporting person sold 12,846 shares at $7.585 per share to satisfy tax withholding, leaving 142,385 shares beneficially owned. The filings note the performance stock units and restricted stock units convert one-for-one to TDOC common stock and describe vesting schedules for those awards.

Form 144 filing for Teladoc Health, Inc. (TDOC) shows proposed sale of 4,149 common shares through Fidelity Brokerage Services with an aggregate market value of $31,490.91, to be sold on or about 09/03/2025 on the NYSE. The filer reports acquiring these shares by restricted stock vesting on 09/01/2025, recorded as compensation. The issuer's outstanding shares are listed as 176,690,662.

The filing also discloses sales by the same person in the past three months: 4,174 shares sold 06/03/2025 for $28,842.34 and 2,383 shares sold 09/02/2025 for $18,075.77. The signer certifies no undisclosed material adverse information.